Midatech Pharma Plc Sponsored ADR Stock

$6.90

3.30% yesterday

Nasdaq, Aug 11, 10:00 pm CET

ISIN

US59564R2031

Symbol

BDRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Midatech Pharma Plc Sponsored ADR Stock price

$6.90

-771,993.11 100.00% 5Y

Nasdaq, Closing price Mon, Aug 11 2025

-0.24 3.30%

ISIN

US59564R2031

Symbol

BDRX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$480.0k

Enterprise Value

$-790.0k

Net debt

positive

Cash

$2.2m

Shares outstanding

26.7m

Valuation (TTM | estimate)

P/E

- | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

0.0

P/B

0.0

Financial Health

Equity Ratio

56.3%

Return on Equity

-68.8%

ROCE

-94.4%

ROIC

-88.5%

Debt/Equity

0.1

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-12.0m | -

EBIT

$-12.4m | $-18.5m

Net Income

$-7.7m | $-93.8m

Free Cash Flow

$-17.5m

Growth (TTM | estimate)

Revenue

-100.0% | -

EBITDA

-15.7% | -

EBIT

-14.8% | -49.7%

Net Income

19.1% | -1,119.9%

Free Cash Flow

-83.9%

EPS

$0.0

FCF per Share

$-0.7

Short interest

0.7%

Employees

Rev per Employee

$0.0

As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.

Get Started for Free Today

Midatech Pharma Plc Sponsored ADR Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Midatech Pharma Plc Sponsored ADR forecast:

6x Buy

86%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Midatech Pharma Plc Sponsored ADR forecast:

Buy

86%

Hold

14%

Analyst Estimates with Stock Price Targets

Financial data from Midatech Pharma Plc Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	5.09 5.09	13% 13% -
- Research and Development Expense	7.30 7.30	34% 34% -
EBITDA	-12 -12	16% 16% -
- Depreciation and Amortization	0.34 0.34	11% 11% -
EBIT (Operating Income) EBIT	-12 -12	15% 15% -
Net Profit	-7.69 -7.69	19% 19% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Midatech Pharma Plc Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

12 days ago

ADR Ratio Change Effective

July 31, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Effective ADSs Outstanding Post Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces the previously announced ratio change of its American Deposi...

Neutral

Accesswire

●

15 days ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

CARDIFF, UK / ACCESS Newswire / July 28, 2025 / Familial Adenomatous Polyposis (FAP) is an inherited condition that puts people at a much greater risk of developing colon cancer. If left untreated, there is a near 100% likelihood that the person will develop colon or rectum cancer.

Neutral

GlobeNewsWire

●

27 days ago

ADR Ratio Change

July 15, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announces a ratio change on its American Depositary Receipts (“ADR”) from one (1) ADR represen...

More Midatech Pharma Plc Sponsored ADR News

Company Profile

Midatech Pharma Plc commercializes oncology treatments and cancer supportive care products through its U.S. commercial organization, Midatech Pharma US. The company engages in the development of pharmaceutical products utilizing its nanomedicine and sustained release technologies. Its pipeline includes MTD119, MTX102, MTD201 and MTX110. Midatech Pharma was founded on September 12, 2014 and is headquartered in Cardiff, the United Kingdom.

Head office	United Kingdom
CEO	Stephen Stamp
Employees	13
Founded	2000
Website	www.biodexapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now